The Air Force has partnered with a private medical company who has developed life-saving technology for the battlefield.
According to Army research, excessive blood loss has reportedly been linked to 90 percent of potentially avoidable deaths from wounds sustained on the battlefield. The Air Force Medical Support Agency is providing technology transition assistance to ReMedX, Inc., to assist with reducing the cost of their wound-treatment invention, XSTAT. This assistance is made possible through the DoD Partnership Intermediary Agreement between the Air Force Research Laboratory and Montana State University/MilTech.
XSTAT was approved for use on the battlefield by the Federal Drug Administration (FDA) in April 2014.
Read more by downloading the full story. You may also contact the AF T3 Program Office for more information by clicking here.
56th Fighter Wing transforms learning with Embry-Riddle partnership
SandTech licenses Air Force patent, forges potential R&D agreement
Ignyte signs into cyber agreement with the Air Force
Research Triangle Firm Enters Agreement with Air Force Venture Unit
New patent license agreement revalues worth of the two birds in the bush
Astronomical society upgrades observatory through an Air Force Academy partnership
Tinker Engineer’s Invention Challenges Mother Nature’s Authority